How do pharmaceutical companies adapt to health insurance fees? The national supplies code is coming.

(2020/06/05) people to middle-aged pharmaceutical companies sales were cut to cry local version of the volume of procurement than the national version of the list of research and development costs: 47 drugs more than 10 million Hengrui medicine accounted for 9; the National Health Insurance Administration issued a national coding supplies to come; another batch of pharmacies de-marketed ..AbbVie recently announced new long-term results for oral JAK inhibitor Rinvoq treatment for rheumatoid arthritis (RA), which showed that oral Rinvoq treatment was treated daily for 72 and 84 weeks and continued to improve symptoms and signs in RA patientsThe safety of Rinvoq monodrug therapy and Rinvoq and MTX combination therapy was consistent with the previously reported RA Summary III safety analysis, and no new safety risks were foundRinvoq inhibits structural joint damagelocal version of the band purchase, it seems to be more aggressive than the national version of the cut pricePharmaceutical companies may be prepared for more brutal challengesThe future return to normal state of the pharmaceutical industry, should be to do research and development of innovative pharmaceutical companies singing the main role, a large number of production of generic drugs to make sales profits of pharmaceutical companies, after the price of water drying, if not transformation only face eliminationdrug price sourrating is a long-term trendas of 2020/6/2, according to incomplete statistics, listed companies have announced the adoption of research and development costs of the adoption of consistency evaluation of drugs (including the adoption of the same) a total of 156From the statistical results, the cost of research and development under 10 million yuan of 109 drugs, accounting for 70%, 10-20 million yuan of 34, accounting for 22%, more than 20 million have 13, accounting for 8%According to the registration classification, of the 20 drugs that passed the consistency evaluation, 13 were drugs with a cost of more than or equal to 10 million yuanHengrui Pharmaceuticals is the largest company with more than 10 million drugs spent on research and developmentthis year affected by the outbreak of new crown pneumonia, the pharmaceutical industry can be described as two days of ice fireAccording to statistics, in the first quarter more than 50% of the Performance of A-share pharmaceutical companies (revenue, net profit) fell, 53 net profit losses, compared with the same period last year only 16As of June 5, a total of 39 pharmaceutical companies disclosed first-half results, more than 40% of the forecast, China Resources 39 expected net profit or more than 1 billion yuan;the demand lag caused by the outbreak will accelerate the response4, the State Administration of Health Insurance issued "on the publicity of medical medical supplies classification and code database of the second batch of medical supplies information notice", the content of the "National Medical Security Administration on the issuance of medical security standardization guidance" related requirements, the second batch of medical supplies information will now be made public supplies are about to establish a consistency evaluation , Zhejiang Provincial health insurance bureau issued the "Zhejiang provincial and Hangzhou City basic medical insurance hospitalization cost DRGs points payment implementation rules (trial)", clear Zhejiang DRGs to achieve the annual total budget system of hospital insurance fund and "balance retention, overspend sharing" of the responsibility sharing mechanism, and detailed the DRG grouping standard, DRG points and difference coefficient, and how the cost settlement the "rules" in other provinces and cities landing DRGs certainly have reference significance On May 15, , Ali Health's market value exceeded 250 billion yuan, surpassing Baidu for the first time For a time, "formerly bat, now Baidu can only be quite a Ali department of the business" said caused a heated discussion In two years, Ali Health's market value has fallen from $50 billion to $250 billion, while Baidu's has fallen from nearly $100 billion to $36 billion Once upon a time, the two were not the same, but now, the business is still irrelevant, but because of market value there is a correlation "When Internet Healthcare Will Be Profitable" has been an industry concern in the last week, retail pharmacies sales notice frequent, currently in Jiangsu, Shandong, Henan, Guangdong, Sichuan, Chongqing, Shaanxi and other places, more than 50 pharmacies to cancel the license to withdraw from the market Combing found that in this batch of securities sales pharmacies, the basic reason is that the enterprise actively applied for cancellation or due did not apply for a replacement In other words, the expiration of the application for a change of issuance, is also the embodiment of the default withdrawal of the company The days of retail pharmacies lying on their backs to make money are over it is understood that recently manufacturers took the lead in raising the factory price of human haemoglobin, to 5g / bottle of this specification, the price has been from the original about 310 yuan or 320 yuan / bottle to the current 340 yuan / bottle The main reason is affected by the outbreak, the first half of this year," domestic pulp production fell, coupled with market expectations of overseas outbreaks affecting human haemoglobin imports can companies take further opportunities?